FDA Oncology Announcements

PDGFR inhibitor × Clear all

5 Announcements

FDA approves avapritinib for advanced systemic mastocytosis

Drug: Ayvakit (avapritinib) · PDGFR inhibitor
Condition: Myeloid

FDA approves ripretinib for advanced gastrointestinal stromal tumor

Trial: INVICTUS
Drug: QINLOCK (ripretinib) · PDGFR inhibitor
Condition: Sarcoma

FDA approves ripretinib for advanced gastrointestinal stromal tumor

Trial: INVICTUS
Drug: QINLOCK (ripretinib) · PDGFR inhibitor
Condition: Sarcoma

FDA approves avapritinib for gastrointestinal stromal tumor with a rare mutation

Drug: AYVAKITTM (avapritinib) · PDGFR inhibitor
Condition: Sarcoma

FDA approves avapritinib for gastrointestinal stromal tumor with a rare mutation

Drug: AYVAKIT (avapritinib) · PDGFR inhibitor
Condition: Sarcoma